Follow The Filings

VRNS Varonis Systems

Varonis Systems earnings company data as of 6:58 AM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 3 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by VRNS's executives, directors and 10% owners in the last 12 months, from their Form 4s

All VRNS insider trades
  • $1.2M bought by 4 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Yakov Faitelson CEO
    Buy
    $599K 26,725 shares at $22.41 +1.2% to stake
    Traded Feb 9 Filed Feb 10
    ↗
  2. David Bass EVP Engineering & CTO
    Buy
    $70K 2,980 shares at $23.47 +0.3% to stake
    Traded Feb 9 Filed Feb 10
    ↗
  3. John J Gavin Jr. Director
    Buy
    $113K 5,000 shares at $22.54 +1.9% to stake
    Traded Feb 6 Filed Feb 10
    ↗
  4. Avrohom J. Kess Director
    Buy
    $397K 17,800 shares at $22.29 +56% to stake
    Traded Feb 6 Filed Feb 10
    ↗

Also filed in the last 12 months, not counted as buying or selling: 20 stock grants, 5 share withholdings for taxes, and 3 gifts.

SEC filings

Recent issuer filings from EDGAR, 16 shown.

Filed Form Detail Links
DEFA14A SOLICITING MATERIAL UNDER 240.14A-12 Filing Doc
DEFA14A SOLICITING MATERIAL UNDER 240.14A-12 Filing Doc
DEFA14A SOLICITING MATERIAL UNDER 240.14A-12 Filing Doc
DEFA14A SOLICITING MATERIAL UNDER 240.14A-12 Filing Doc
DEFA14A CURRENT REPORT Filing Doc
8-K 1.01,5.02,7.01,9.01 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.02,5.07 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated about 14 hours ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.